Telix Pharmaceuticals Limited (TLX)
| Market Cap | 3.96B +25.5% |
| Revenue (ttm) | 890.79M +33.5% |
| Net Income | 33.50M +183.8% |
| EPS | 0.10 +174.8% |
| Shares Out | 339.78M |
| PE Ratio | 118.29 |
| Forward PE | 514.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 86,687 |
| Open | 11.70 |
| Previous Close | 11.45 |
| Day's Range | 11.61 - 11.78 |
| 52-Week Range | 6.28 - 12.48 |
| Beta | 0.60 |
| Analysts | Strong Buy |
| Price Target | 21.49 (+83.13%) |
| Earnings Date | Aug 20, 2026 |
About TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for TLX stock is "Strong Buy." The 12-month stock price target is $21.49, which is an increase of 83.13% from the latest price.
News
Telix Completes Patient Enrollment In BiPASS Trial, Aligns With FDA On NDA Filing; Stock Up
(RTTNews) - Telix Pharmaceuticals Limited (TLX), a commercial-stage biopharmaceutical company, on Wednesday reported completion of patient enrollment in the Phase 3 BiPASS study, evaluating its commer...
6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More
(RTTNews) - Today's after-hours gainers in the healthcare sector included Universe Pharmaceuticals, which drew attention after disclosing multiple Schedule 13G filings; bioAffinity Technologies, which...
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
MELBOURNE, Australia and INDIANAPOLIS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced completion of patient enrollment in the Phase 3...
Telix Appoints Gill As Board Chairman
(RTTNews) - Telix Pharmaceuticals Limited (TLX), a commercial-stage biopharmaceutical company, on Tuesday announced the appointment of David Gill as Chair of the Board, effective immediately.
Telix Appoints David Gill as Chair
MELBOURNE, Australia and INDIANAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix” or the “Company”) today announces that David Gill has been appoi...
Telix Pharmaceuticals (ASX:TLX) -- Navigating Regulatory Challenges | WS Amati Global ...
Telix Pharmaceuticals (ASX:TLX) -- Navigating Regulatory Challenges | WS Amati Global Innovation Fund Q3 2025
Telix Pharma H1 Revenue Jumps 22%; Reaffirms FY2026 Revenue Guidance; Stock Up
(RTTNews) - Telix Pharmaceuticals Ltd. (TLX), a commercial-stage radiopharmaceutical company, announced financial results for the half-year, reflecting 22% revenue growth and swinging to profit before...
Telix Pharmaceuticals H1 Earnings Call Highlights
Telix Pharmaceuticals NASDAQ: TLX reported first-half 2026 revenue of $477 million, up 22% from the prior-year period, as demand for its precision medicine imaging products continued to grow. The comp...
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June ...
Telix Pharmaceuticals Earnings Call Transcript: H1 2026
Revenue grew 22% year-on-year to $477 million, driven by strong precision medicine sales and successful product launches. Regulatory and clinical milestones were achieved, with continued investment in R&D and manufacturing to support future growth. Guidance remains at the upper end of AUD 950–970 million for 2026.
Telix Pharmaceuticals Quarterly report: H1 2026
Telix Pharmaceuticals has published its H1 2026 quarterly earnings report on August 19, 2026.
Telix Pharmaceuticals Earnings release: H1 2026
Telix Pharmaceuticals released its H1 2026 earnings on August 19, 2026, summarizing the period's financial results.
Telix Pharmaceuticals Slides: H1 2026
Telix Pharmaceuticals has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 19, 2026.
Telix to Host R&D Day in New York City on September 22, 2026
MELBOURNE, Australia and INDIANAPOLIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will host a Research and Development (R&D)...
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT...
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational perfo...
Telix Pharmaceuticals Earnings release: Q2 2026
Telix Pharmaceuticals released its Q2 2026 earnings on July 20, 2026, summarizing the period's financial results.
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
MELBOURNE (Australia) and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced that the first patient has been dosed with TLX2...
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
MELBOURNE, Australia and INDIANAPOLIS, July 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and St Vincent's Hospital today announced that the first patient...
FDA Alignment to Advance ProstACT Global Phase 3 Trial
MELBOURNE, Australia and INDIANAPOLIS, July 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX, “Telix”) today announced the successful outcome of a Type B meeting with the Unit...
Telix Pharmaceuticals Transcript: Status update
The neuro-oncology pipeline features TLX101 in phase III for recurrent glioblastoma, with strong safety and promising survival data. Pixclara (FET-PET) enhances diagnostic accuracy and is under FDA review. Experts highlight the rarity of complete responses with current care and the potential of theranostic approaches to transform outcomes.
Telix Pharmaceuticals Slides: Status update
Telix Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces an educational webinar exploring the unmet needs...
Telix Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted a robust theranostics pipeline, strong PSMA market share, and strategic vertical integration. Key clinical trials in prostate, brain, and renal cancers are advancing, with new collaborations and underappreciated FAP assets poised for future growth.
Telix Pharmaceuticals Transcript: 46th Annual William Blair Growth Stock Conference
A global radiopharma innovator highlighted robust commercial growth, expanding global reach, and a strong pipeline in prostate, kidney, and brain cancers. Key products and partnerships drive revenue and support self-funded R&D, with multiple late-stage trials underway.